Please select the option that best describes you:
Topics:
Rheumatology • Systemic lupus erythematosus
In managing non-renal SLE, how do you approach choosing between belimumab and anifrolumab?
Is there a role for cytokine profiling to assess the involvement of adaptive versus innate immune pathways?
Can genetic testing or epigenetic markers—such as methylation or hypomethylation of interferon-regulated genes—inform treatment decisions?
Lastly, is there clinical utility in integrating cytokine panels with validated lupus activity markers (e.g., anti-dsDNA, anti-Smith antibodies, complement levels) as part of a precision medicine strategy in routine practice?
Answer from: at Academic Institution
This is a complex but important question, and I typically begin by clarifying the organ system involved, the severity of disease, previous treatment history—particularly any failure of conventional DMARDs—and the current steroid burden, as this greatly influences the choice of biologic.
...
Thank you so much Dr. @Donald E. Thomas.